References
- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–2040.
- Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. 2021.
- Israel A, Shenhar Y, Green I, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines. 2021;10(1):64.
- Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13(1):80.
- Heitmann JS, Bilich T, Tandler C, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022;601(7894):617–622.
- Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant. Nat Med. 2022;28(3):472–476.
- Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193.
- Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature. 2022;603(7901):493–496.
- Peng Y, Felce SL, Dong D, et al. An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol. 2022;23(1):50–61.
- Kedzierska K, Thomas PG. Count on us: t cells in SARS-CoV-2 infection and vaccination. Cell Rep Med. 2022;3(3):100562.
- Bjorkander S, Du L, Zuo F, et al. SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults. J Allergy Clin Immunol. 2022;149(1):65–75 e8.
- Marklund E, Leach S, Nystrom K, et al. Longitudinal follow up of immune responses to SARS-CoV-2 in health care workers in Sweden with several different commercial IgG-Assays, measurement of neutralizing antibodies and CD4(+) T-cell responses. Front Immunol. 2021;12:750448.
- Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533–1535.
- Notarte KI, Ver AT, Velasco JV, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59(6):373–390.